Advertisement

Digestive Diseases and Sciences

, Volume 64, Issue 12, pp 3463–3470 | Cite as

Use of the Electronic Health Record to Target Patients for Non-endoscopic Barrett’s Esophagus Screening

  • Brittany L. Baldwin-Hunter
  • Rita M. Knotts
  • Samantha D. Leeds
  • Joel H. Rubenstein
  • Charles J. Lightdale
  • Julian A. AbramsEmail author
Original Article
  • 90 Downloads

Abstract

Background

Clinical prediction models targeting patients for Barrett’s esophagus (BE) screening include data obtained by interview, questionnaire, and body measurements. A tool based on electronic health records (EHR) data could reduce cost and enhance usability, particularly if combined with non-endoscopic BE screening methods.

Aims

To determine whether EHR-based data can identify BE patients.

Methods

We performed a retrospective review of patients ages 50–75 who underwent a first-time esophagogastroduodenoscopy. Data extracted from the EHR included demographics and BE risk factors. Endoscopy and pathology reports were reviewed for histologically confirmed BE. Screening criteria modified from clinical guidelines were assessed for association with BE. Subsequently, a score based on multivariate logistic regression was developed and assessed for its ability to identify BE subjects.

Results

A total of 2931 patients were assessed, and BE was found in 1.9%. Subjects who met screening criteria were more likely to have BE (3.3% vs. 1.1%, p = 0.001), and the criteria predicted BE with an AUROC of 0.65 (95% CI 0.59–0.71). A score based on logistic regression modeling included gastroesophageal reflux disease, sex, body mass index, and ever-smoker status and identified BE subjects with an AUROC of 0.71 (95% CI 0.64–0.77). Both prediction tools produced higher AUROCs in women than in men.

Conclusions

EHR-based BE risk prediction tools identify BE patients with fair accuracy. While these tools may improve the efficiency of patient targeting for BE screening in the primary care setting, challenges remain to identify high-risk patients for non-invasive BE screening in clinical practice.

Keywords

Esophageal adenocarcinoma Risk Prediction Model Criteria 

Notes

Compliance with Ethical Standards

Conflict of interest

Julian Abrams has consulted for Medtronic.

Supplementary material

10620_2019_5707_MOESM1_ESM.docx (14 kb)
Supplementary material 1 (DOCX 13 kb)

References

  1. 1.
    Abrams JA, Sharaiha RZ, Gonsalves L, Lightdale CJ, Neugut AI. Dating the rise of esophageal adenocarcinoma: analysis of connecticut tumor registry data, 1940–2007. Cancer Epidemiol Biomark Prev. 2011;20:183–186.  https://doi.org/10.1158/1055-9965.EPI-10-0802.CrossRefGoogle Scholar
  2. 2.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30.  https://doi.org/10.3322/caac.21442.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Njei B, McCarty TR, Birk JW. Trends in esophageal cancer survival in United States adults from 1973 to 2009: a SEER database analysis. J Gastroenterol Hepatol. 2016;31:1141–1146.  https://doi.org/10.1111/jgh.13289.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Cooper GS, Kou TD, Chak A. Receipt of previous diagnoses and endoscopy and outcome from esophageal adenocarcinoma: a population-based study with temporal trends. Am J Gastroenterol. 2009;104:1356–1362.  https://doi.org/10.1038/ajg.2009.159.CrossRefPubMedGoogle Scholar
  5. 5.
    El-Serag HB, Naik AD, Duan Z, et al. Surveillance endoscopy is associated with improved outcomes of oesophageal adenocarcinoma detected in patients with Barrett’s oesophagus. Gut. 2016;65:1252–1260.  https://doi.org/10.1136/gutjnl-2014-308865.CrossRefPubMedGoogle Scholar
  6. 6.
    Qiao Y, Hyder A, Bae SJ, et al. Surveillance in patients with Barrett’s esophagus for early detection of esophageal adenocarcinoma: a systematic review and meta-analysis. Clin Transl Gastroenterol. 2015;6:e131.  https://doi.org/10.1038/ctg.2015.58.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Wang KK, Sampliner RE. Practice parameters Committee of the American College of G. updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett’s esophagus. Am J Gastroenterol. 2008;103:788–797.  https://doi.org/10.1111/j.1572-0241.2008.01835.x.CrossRefPubMedGoogle Scholar
  8. 8.
    Tramontano AC, Sheehan DF, Yeh JM, et al. The impact of a prior diagnosis of Barrett’s esophagus on esophageal adenocarcinoma survival. Am J Gastroenterol. 2017;112:1256–1264.  https://doi.org/10.1038/ajg.2017.82.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Verbeek RE, Leenders M, Ten Kate FJ, et al. Surveillance of Barrett’s esophagus and mortality from esophageal adenocarcinoma: a population-based cohort study. Am J Gastroenterol. 2014;109:1215–1222.  https://doi.org/10.1038/ajg.2014.156.CrossRefPubMedGoogle Scholar
  10. 10.
    Phoa KN, van Vilsteren FG, Weusten BL, et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA. 2014;311:1209–1217.  https://doi.org/10.1001/jama.2014.2511.CrossRefPubMedGoogle Scholar
  11. 11.
    Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med. 2009;360:2277–2288.  https://doi.org/10.1056/NEJMoa0808145.CrossRefPubMedGoogle Scholar
  12. 12.
    American Gastroenterological A, Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American Gastroenterological Association medical position statement on the management of Barrett’s esophagus. Gastroenterology. 2011;140:1084–1091.  https://doi.org/10.1053/j.gastro.2011.01.030.CrossRefGoogle Scholar
  13. 13.
    Chan DK, Zakko L, Visrodia KH, et al. Breath testing for Barrett’s esophagus using exhaled volatile organic compound profiling with an electronic nose device. Gastroenterology. 2017;152:24–26.  https://doi.org/10.1053/j.gastro.2016.11.001.CrossRefPubMedGoogle Scholar
  14. 14.
    di Pietro M, Chan D, Fitzgerald RC, Wang KK. Screening for Barrett’s esophagus. Gastroenterology. 2015;148:912–923.  https://doi.org/10.1053/j.gastro.2015.02.012.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Iyer PG, Taylor WR, Johnson ML, et al. Highly discriminant methylated DNA markers for the non-endoscopic detection of Barrett’s esophagus. Am J Gastroenterol. 2018;113:1156–1166.  https://doi.org/10.1038/s41395-018-0107-7.CrossRefPubMedGoogle Scholar
  16. 16.
    Shaheen NJ, Falk GW, Iyer PG, Gerson LB. American College of G. ACG clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol. 2016;111:30–50.  https://doi.org/10.1038/ajg.2015.322.CrossRefPubMedGoogle Scholar
  17. 17.
    Ross-Innes CS, Debiram-Beecham I, O’Donovan M, et al. Evaluation of a minimally invasive cell sampling device coupled with assessment of trefoil factor 3 expression for diagnosing Barrett’s esophagus: a multi-center case-control study. PLoS Med. 2015;12:e1001780.  https://doi.org/10.1371/journal.pmed.1001780.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Snider EJ, Compres G, Freedberg DE, et al. Barrett’s esophagus is associated with a distinct oral microbiome. Clin Transl Gastroenterol. 2018;9:135.  https://doi.org/10.1038/s41424-018-0005-8.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Edelstein ZR, Bronner MP, Rosen SN, Vaughan TL. Risk factors for Barrett’s esophagus among patients with gastroesophageal reflux disease: a community clinic-based case-control study. Am J Gastroenterol. 2009;104:834–842.  https://doi.org/10.1038/ajg.2009.137.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Gerson LB, Edson R, Lavori PW, Triadafilopoulos G. Use of a simple symptom questionnaire to predict Barrett’s esophagus in patients with symptoms of gastroesophageal reflux. Am J Gastroenterol. 2001;96:2005–2012.  https://doi.org/10.1111/j.1572-0241.2001.03933.x.CrossRefPubMedGoogle Scholar
  21. 21.
    Ireland CJ, Fielder AL, Thompson SK, Laws TA, Watson DI, Esterman A. Development of a risk prediction model for Barrett’s esophagus in an Australian population. Dis Esophagus. 2017;30:1–8.  https://doi.org/10.1093/dote/dox033.CrossRefPubMedGoogle Scholar
  22. 22.
    Liu X, Wong A, Kadri SR, et al. Gastro-esophageal reflux disease symptoms and demographic factors as a pre-screening tool for Barrett’s esophagus. PLoS ONE. 2014;9:e94163.  https://doi.org/10.1371/journal.pone.0094163.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Locke GR, Zinsmeister AR, Talley NJ. Can symptoms predict endoscopic findings in GERD? Gastrointest Endosc. 2003;58:661–670.CrossRefGoogle Scholar
  24. 24.
    Rubenstein JH, Morgenstern H, Appelman H, et al. Prediction of Barrett’s esophagus among men. Am J Gastroenterol. 2013;108:353–362.  https://doi.org/10.1038/ajg.2012.446.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Thrift AP, Kendall BJ, Pandeya N, Vaughan TL, Whiteman DC, Study of Digestive H. A clinical risk prediction model for Barrett esophagus. Cancer Prev Res (Phila). 2012;5:1115–1123.  https://doi.org/10.1158/1940-6207.capr-12-0010.CrossRefGoogle Scholar
  26. 26.
    Eloubeidi MA, Provenzale D. Clinical and demographic predictors of Barrett’s esophagus among patients with gastroesophageal reflux disease: a multivariable analysis in veterans. J Clin Gastroenterol. 2001;33:306–309.CrossRefGoogle Scholar
  27. 27.
    Ford AC, Forman D, Reynolds PD, Cooper BT, Moayyedi P. Ethnicity, gender, and socioeconomic status as risk factors for esophagitis and Barrett’s esophagus. Am J Epidemiol. 2005;162:454–460.  https://doi.org/10.1093/aje/kwi218.CrossRefPubMedGoogle Scholar
  28. 28.
    Corley DA, Kubo A, Zhao W. Abdominal obesity and the risk of esophageal and gastric cardia carcinomas. Cancer Epidemiol Biomark Prev. 2008;17:352–358.  https://doi.org/10.1158/1055-9965.EPI-07-0748.CrossRefGoogle Scholar
  29. 29.
    Abrams JA, Fields S, Lightdale CJ, Neugut AI. Racial and ethnic disparities in the prevalence of Barrett’s esophagus among patients who undergo upper endoscopy. Clin Gastroenterol Hepatol. 2008;6:30–34.  https://doi.org/10.1016/j.cgh.2007.10.006.CrossRefPubMedGoogle Scholar
  30. 30.
    Anderson LA, Watson RG, Murphy SJ, et al. Risk factors for Barrett’s oesophagus and oesophageal adenocarcinoma: results from the FINBAR study. World J Gastroenterol. 2007;13:1585–1594.CrossRefGoogle Scholar
  31. 31.
    Corley DA, Kubo A, Levin TR, et al. Abdominal obesity and body mass index as risk factors for Barrett’s esophagus. Gastroenterology. 2007;133:34–41.  https://doi.org/10.1053/j.gastro.2007.04.046.CrossRefPubMedGoogle Scholar
  32. 32.
    Rubenstein JH, Mattek N, Eisen G. Age- and sex-specific yield of Barrett’s esophagus by endoscopy indication. Gastrointest Endosc. 2010;71:21–27.  https://doi.org/10.1016/j.gie.2009.06.035.CrossRefPubMedGoogle Scholar
  33. 33.
    Smith KJ, O’Brien SM, Green AC, Webb PM, Whiteman DC, Study of Digestive H. Current and past smoking significantly increase risk for Barrett’s esophagus. Clin Gastroenterol Hepatol. 2009;7:840–848.  https://doi.org/10.1016/j.cgh.2009.04.018.CrossRefPubMedGoogle Scholar
  34. 34.
    Spechler SJ, Jain SK, Tendler DA, Parker RA. Racial differences in the frequency of symptoms and complications of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2002;16:1795–1800.CrossRefGoogle Scholar
  35. 35.
    Whiteman DC, Sadeghi S, Pandeya N, et al. Combined effects of obesity, acid reflux and smoking on the risk of adenocarcinomas of the oesophagus. Gut. 2008;57:173–180.  https://doi.org/10.1136/gut.2007.131375.CrossRefPubMedGoogle Scholar
  36. 36.
    Le CT. A solution for the most basic optimization problem associated with an ROC curve. Stat Methods Med Res. 2006;15:571–584.  https://doi.org/10.1177/0962280206070637.CrossRefPubMedGoogle Scholar
  37. 37.
    Rubenstein JH, Scheiman JM, Sadeghi S, Whiteman D, Inadomi JM. Esophageal adenocarcinoma incidence in individuals with gastroesophageal reflux: synthesis and estimates from population studies. Am J Gastroenterol. 2011;106:254–260.  https://doi.org/10.1038/ajg.2010.470.CrossRefPubMedGoogle Scholar
  38. 38.
    Thrift AP, Kendall BJ, Pandeya N, Whiteman DC. A model to determine absolute risk for esophageal adenocarcinoma. Clin Gastroenterol Hepatol. 2013;11:138–144e2.  https://doi.org/10.1016/j.cgh.2012.10.026.CrossRefPubMedGoogle Scholar
  39. 39.
    Xie SH, Lagergren J. A model for predicting individuals’ absolute risk of esophageal adenocarcinoma: moving toward tailored screening and prevention. Int J Cancer. 2016;138:2813–2819.  https://doi.org/10.1002/ijc.29988.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Brittany L. Baldwin-Hunter
    • 1
  • Rita M. Knotts
    • 2
  • Samantha D. Leeds
    • 1
  • Joel H. Rubenstein
    • 3
    • 4
  • Charles J. Lightdale
    • 1
  • Julian A. Abrams
    • 1
    Email author
  1. 1.Division of Digestive and Liver DiseasesColumbia University Medical CenterNew YorkUSA
  2. 2.Division of Gastroenterology and HepatologyNew York University School of MedicineNew YorkUSA
  3. 3.Veterans Affairs Center for Clinical Management ResearchAnn ArborUSA
  4. 4.Barrett’s Esophagus Program, Division of GastroenterologyUniversity of MichiganAnn ArborUSA

Personalised recommendations